4602-73-7

Basic information

• Product Name: 7-Hydroxy-6-methoxy-3,4-dihydroisoquinoline
• Synonyms: 7-HYDROXY-6-METHOXY-3,4-DIHYDROISOQUINOLINE;3,4-DIHYDRO-7-HYDROXY-6-METHOXYISOQUINOLINE;7-HYDROXY-6-METHOXY-3,4-DIHYDROISOQUINOLINE 98%;6-Methoxy-7-hydroxy-3,4-dihydro-isoquinoline;7-Hydroxy-6-methoxy-3,4-dihydroisoquinoline,98%;6-Methoxy-3,4-dihydroisoquinolin-7-ol
• CAS NO: 4602-73-7
• Molecular Formula: C₁₀H₁₁NO₂
• Molecular Weight: 177.2
• EINECS: -0
• Mol File: 4602-73-7.mol
• Article Data: 4

Chemical Properties

• Melting Point: 187-191 °C
• Boiling Point: 332.1ºC at 760 mmHg
• Flash Point: 154.6ºC
• Appearance: /
• Density: 1.26g/cm3
• Vapor Pressure: 7.74E-05mmHg at 25°C
• Refractive Index: 1.69
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.73±0.20(Predicted)
• Water Solubility: SOLUBLE IN HOT WATER
• CAS DataBase Reference: 7-Hydroxy-6-methoxy-3,4-dihydroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Hydroxy-6-methoxy-3,4-dihydroisoquinoline(4602-73-7)
• EPA Substance Registry System: 7-Hydroxy-6-methoxy-3,4-dihydroisoquinoline(4602-73-7)

Safety Data

• Hazard Codes: Xn
• Statements: 36/38-21/22
• Safety Statements: 36/37/39-26
• Hazardous Substances Data: 4602-73-7(Hazardous Substances Data)

Usage

Chemical Properties

yellow crystalline powder and flakes

Uses

7-Hydroxy-6-methoxy-3,4-dihydroisoquinoline acts as a reagent for the synthesis and dual dopamine D1 receptor agonist/D2 receptor antagonist activity, and SAR of tetrahydroisoquinolines for treating schizophrenia.

InChI:InChI=1/C9H7NO/c11-9-2-1-7-3-4-10-6-8(7)5-9/h1-6,11H

Upstream product

• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 282721-32-8 N-[2-(4-hydroxy-3-methoxyphenyl)ethyl]formamide 
• 3382-18-1 6,7-dimethoxy-3,4-dihydro-isoquinoline 
• 55803-41-3 N-formyl-2-[3-methoxy-4-(benzyloxy)phenyl]ethylamine 

Downstream Products

• 111599-06-5 (7-Hydroxy-6-methoxy-1,2,3,4-tetrahydro-isoquinolin-1-yl)-acetic acid 
• 111599-04-3 (7-Hydroxy-6-methoxy-1,2,3,4-tetrahydro-isoquinolin-1-yl)-acetic acid ethyl ester 
• 1426260-82-3 8-(2,4-dimethoxyphenyl)-2-(2-fluorophenethyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-61-8 2-(2-fluorophenethyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-65-2 8-bromo-2-(2-chlorophenethyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1426260-64-1 8-bromo-6-methoxy-2-(4-nitrophenethyl)-1,2,3,4-tetrahydroisoquinolin-7-ol 

Relevant articles and documents

Peganumine A alkaloid structure simplifier and application thereof

The invention discloses a Peganumine A alkaloid structure simplifier, a stereoisomer or a pharmaceutical salt thereof. The structure is shown in the following general formula: each substituent group is defined in the specification. The simplified structure of the Peganumine A alkaloid provided by the invention has a relatively obvious proliferation inhibition effect on liver cancer HepG2, lung cancer A549 and intestinal cancer HCT116, and the anti-tumor activity of part of compounds is higher than the anti-liver cancer HepG2 activity of Peganumine A reported in literatures.

PHARMACEUTICAL COMPOUNDS

This application describes substituted 1,3,4,6,7,11b-hexahydro-benzo(a)quinolizine compounds, pharmaceutical compositions containing them, processes for making them and their therapeutic methods.